miRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation

Ma,Tao; Yang,Lu; Zhang,Jin

doi:10.3892/or.2015.3713

miRNA‑542‑3p downregulation promotes trastuzumab resistance in breast cancer cells via AKT activation

Authors:
- Tao Ma
- Lu Yang
- Jin Zhang
View Affiliations

Affiliations: The Third Department of Breast Cancer, China Tianjin Breast Cancer Prevention, Treatment and Research Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Tianjin 300060, P.R. China
Published online on: January 13, 2015 https://doi.org/10.3892/or.2015.3713
Pages: 1215-1220

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Trastuzumab (Herceptin) has been widely used in breast cancer treatment. However, the majority of cancers that initially respond to trastuzumab begin to progress again within 1 year. Despite the high resistance rate, the molecular mechanisms underlying this desease are not well understood. In the present study, microRNA (miRNA‑542‑3p modulated trastuzumab resistance in SKBR3 and MCF7/Her2 breast cancer cell lines. Trastuzumab induced miRNA‑542‑3p expression in SKBR3 and MCF7/Her2 cells. Furthermore, knockdown of miRNA‑542‑3p in the two cell lines resulted in decreased drug sensitivity to trastuzumab and cell apoptosis. The blockage of G1/S checkpoint by trastuzumab was rescued as well. miRNA‑542‑3p knockdown also activated the phosphatidylinositol 3‑kinase (PI3K)‑Akt pathway, while LY294002 reversed the effect of miRNA‑542‑3p knockdown. In summary, the results suggested that miRNA‑542‑3p downregulation may contribute to the trastuzumab resistance in breast cancer via, at least in part, the PI3K‑akt pathway. Our findings provide new molecular mechanisms in trastuzumab resistance.

View Figures

View References

1	Siegel R, Ma J, Zou Z and Jemal A: Cancer statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
2	Hynes NE and MacDonald G: ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol. 21:177–184. 2009. View Article : Google Scholar : PubMed/NCBI
3	Baselga J and Swain SM: Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 9:463–475. 2009. View Article : Google Scholar : PubMed/NCBI
4	Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM and Fox JA: Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol. 26:60–70. 1999.PubMed/NCBI
5	Pohlmann PR, Mayer IA and Mernaugh R: Resistance to trastuzumab in breast cancer. Clin Cancer Res. 15:7479–7491. 2009. View Article : Google Scholar : PubMed/NCBI
6	Nahta R and Esteva FJ: Herceptin: mechanisms of action and resistance. Cancer Lett. 232:123–138. 2006. View Article : Google Scholar : PubMed/NCBI
7	Hudis CA: Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med. 357:39–51. 2007. View Article : Google Scholar : PubMed/NCBI
8	Nahta R and Esteva FJ: Trastuzumab: triumphs and tribulations. Oncogene. 26:3637–3643. 2007. View Article : Google Scholar : PubMed/NCBI
9	Valabrega G, Montemurro F and Aglietta M: Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 18:977–984. 2007. View Article : Google Scholar : PubMed/NCBI
10	He L and Hannon GJ: MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 5:522–531. 2004. View Article : Google Scholar : PubMed/NCBI
11	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
12	Oneyama C, Morii E, Okuzaki D, et al: MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene. 31:1623–1635. 2012. View Article : Google Scholar
13	Yoon S, Choi YC, Lee S, Jeong Y, Yoon J and Baek K: Induction of growth arrest by miR-542-3p that targets survivin. FEBS Lett. 584:4048–4052. 2010. View Article : Google Scholar : PubMed/NCBI
14	He T, Qi F, Jia L, et al: MicroRNA-542-3p inhibits tumour angiogenesis by targeting angiopoietin-2. J Pathol. 232:499–508. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lee S, Yang W, Lan KH, et al: Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2- overexpressing breast cancer cells. Cancer Res. 62:5703–5710. 2002.PubMed/NCBI
16	Baselga J, Norton L, Albanell J, Kim YM and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res. 58:2825–2831. 1998.PubMed/NCBI
17	Vivanco I and Sawyers CL: The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer. 2:489–501. 2002. View Article : Google Scholar : PubMed/NCBI
18	Greer EL and Brunet A: FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene. 24:7410–7425. 2005. View Article : Google Scholar : PubMed/NCBI
19	Wu Y, Shang X, Sarkissyan M, Slamon D and Vadgama JV: FOXO1A is a target for HER2-overexpressing breast tumors. Cancer Res. 70:5475–5485. 2010. View Article : Google Scholar : PubMed/NCBI
20	Sumikawa T, Shigeoka Y, Igishi T, et al: Dexamethasone interferes with trastuzumab-induced cell growth inhibition through restoration of AKT activity in BT-474 breast cancer cells. Int J Oncol. 32:683–688. 2008.PubMed/NCBI
21	Grell P, Fabian P, Khoylou M, et al: Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int J Oncol. 41:1204–1212. 2012.PubMed/NCBI
22	Chung SS, Giehl N, Wu Y and Vadgama JV: STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits. Int J Oncol. 44:403–411. 2014.
23	Davis R, Singh KP, Kurzrock R and Shankar S: Sulforaphane inhibits angiogenesis through activation of FOXO transcription factors. Oncol Rep. 22:1473–1478. 2009.PubMed/NCBI
24	Han J, Pan XY, Xu Y, et al: Curcumin induces autophagy to protect vascular endothelial cell survival from oxidative stress damage. Autophagy. 8:812–825. 2012. View Article : Google Scholar : PubMed/NCBI
25	Zhou J, Liao W, Yang J, et al: FOXO3 induces FOXO1-dependent autophagy by activating the AKT1 signaling pathway. Autophagy. 8:1712–1723. 2012. View Article : Google Scholar : PubMed/NCBI
26	Chakrabarty A, Bhola NE, Sutton C, et al: Trastuzumab-resistant cells rely on a HER2-PI3K-FoxO-survivin axis and are sensitive to PI3K inhibitors. Cancer Res. 73:1190–1200. 2013. View Article : Google Scholar :
27	Engelman JA: Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009. View Article : Google Scholar : PubMed/NCBI
28	Fruman DA and Rommel C: PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov. 13:140–156. 2014. View Article : Google Scholar : PubMed/NCBI